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In this paper a method for the simultaneous quantifi-
cation of the anti-fungal drug itraconazole and its 
co-active metabolite hydroxyitraconazole in plasma
employing liquid chromatography tandem-mass spec-
trometry and automated solid-phase extraction is de-
scribed. The method proved rugged, enables short
turn-around times and is highly specific. Since there is
growing evidence for the importance of therapeutic
drug monitoring of itraconazole in the prophylaxis and
treatment of invasive fungal infections, the method
described here is of interest for a large number of ter-
tiary care hospital laboratories. Clin Chem Lab Med
2003; 41(7):915–920
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Introduction
Invasive fungal infections have increased in incidence
over the past years and now are among the most fre-
quent causes of morbidity and mortality in immuno-
compromised patients, particularly in patients with
neutropenia (1, 2). Amphotericin B desoxycholate is
currently the standard empirical anti-fungal therapy in
neutropenic patients with malignancies, who have per-
sistent fever that does not respond to broad-spectrum
antibacterial treatment (3). This therapy, however, is
accompanied by severe side effects. Itraconazole is a
new less toxic alternative for amphotericin B. Efficiency
could be demonstrated for prophylaxis of fungal infec-
tions (4, 5), for empirical anti-fungal therapy (6), as well
as for the treatment of proven invasive aspergillosis
(7).
Itraconazole is a triazole compound, with activity
against Aspergillus fumigatus and Candida species as
the most relevant fungal pathogens in neutropenic pa-
tients; it is meanwhile available as an intravenous and
an oral formulation. Often itraconazole therapy is
started with intravenous application and is subse-
quently switched to oral application for longer time pe-
riods (8, 9). The drug is highly lipophilic and only ion-
ized at low pH (pKa = 3.7 (10)). The absolute availability
of capsules in healthy volunteers under fasting condi-
tions is about 55%; it is increased after a meal and
markedly reduced by antacida. In immuno-compro-
mised patients the absorption of itraconazole is often
affected by gastrointestinal disorders caused by cyto-
toxic chemotherapy or graft-versus-host disease. Itra-
conazole is 99.8% bound to human plasma proteins
and its apparent volume of distribution is about 11 l/kg.
The drug is extensively metabolized by hepatic cy-
tochrome-P450 (CYP) enzymes (10, 11). Among the
metabolites hydroxyitraconazole is of particular inter-
est because it exerts anti-fungal activity similar to that
of itraconazole (12) and typical plasma concentrations
are usually slightly higher compared to that of itra-
conazole. Co-administration of itraconazole with drugs
that inhibit CYP3A4 can lead to increased serum con-
centrations (e.g., macrolide antibiotics such as ery-
thromycin, HIV protease inhibitors such as indinavir),
whereas inductors of CYP3A4 can decrease serum con-
centrations of itraconazole (e.g., phenytoin, carba-
mazepine, isoniazid, rifabutin, inhibitors of reverse
transcriptase such as nevirapine, immunosuppres-
sants such as cyclosporine). After a single oral dose,
the terminal elimination half-life of itraconazole is
about 24 hours. The drug exhibits a dose-dependent
saturable pharmacokinetic behavior. Renal failure
hardly affects the pharmacokinetic properties of itra-
conazole but little is known about the effects of hepatic
failure. Itraconazole is in general well tolerated; gas-
trointestinal disturbances and dizziness are the most
frequently reported adverse effects. However, in ani-
mals negative inotropic effects have been shown, and
there is concern about cases of severe liver toxicity
possibly associated with itraconazole treatment (13).
Given a marked intra- and inter-patient variability in
the pharmacokinetics of itraconazole, dose individual-
ization of itraconazole according to trough plasma lev-
els has meanwhile been shown to be useful. Target
trough plasma concentrations of at least 500 ng/ml are
recommended for prophylaxis of invasive fungal infec-
tions (14–17), whereas higher trough levels are proba-
bly beneficial in cases of infection.
It is evident from this background that the availabil-
ity of reliable analytical methods for the quantification
of itraconazole in plasma is of growing importance for
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laboratories in tertiary care hospitals. Numerous HPLC
methods for this purpose employing different tech-
niques of sample preparation and detection have been
published and are in clinical use (18–31). High analyt-
ical specificity is of particular importance for thera-
peutic drug monitoring of itraconazole since patients
receiving itraconazole for prophylaxis or treatment of
fungal infections are usually treated with several other
drugs and these drugs or their respective metabolites
may potentially interfere with itraconazole quantifica-
tion. More importantly, simultaneous quantification of
itraconazole and hydroxyitraconazole in plasma using
non-specific techniques of HPLC detection and iso-
cratic elution is in our experience problematic due to
co-eluting “endogenous” peaks in individual blank
samples. Because liquid chromatography-tandem mass
spectrometry (LC-TMS) at present offers the highest
attainable analytical specificity for drug monitoring we
decided to develop a LC-TMS method for the determi-
nation of itraconazole and hydroxyitraconazole in
plasma with automated sample preparation allowing




Itraconazole, hydroxyitraconazole and the compound R51012
(a dimethyl homolog of itraconazole) used as the internal
standard were obtained from ORTHO BIOTECH (Neuss, Ger-
many) (Figure 1A and B); stock solutions of these compounds
were made in methanol (approx. 50 mg/l). Ammonium acetate
was from Merck (Darmstadt, Germany); a 200 mM stock solu-
tion was made in water. Methanol and water were of HPLC
grade (Baker, Deventer, The Netherlands).
Instruments
A Waters Alliance 2690 HPLC module (Waters, Milford, USA)
was used, coupled to a Micromass Quattro LC-tandem mass
spectrometry system (Micromass, Manchester, UK) with a
split of approximately 1:10.
Standards
A stock calibrator was prepared by spiking a plasma pool from
patients not treated with itraconazole with the stock solutions
of itraconazole and hydroxyitraconazole, respectively, to ob-
tain concentrations of 4000 µg/l for both analytes. After care-
ful mixing and overnight equilibration, working calibrators
with the following concentrations were prepared by serial di-
lution: 2000, 1000, 500, 250, 125, 62.5 µg/l; a zero-calibrator
was used additionally.
Sample preparation and chromatography
A semi-automated sample preparation with a manual depro-
teinization step and automated on-line solid-phase extraction
employing column-switching was applied.
In 1.5 ml polypropylene cups, 50 µl of calibrators or pa-
tients’ plasma samples were precipitated with 150 µl of ace-
tonitrile containing the internal standard at a concentration of
1000 µg/l. After vigorous vortex mixing the samples were cen-
trifuged using a non-thermostated standard benchtop cen-
trifuge for 10 min at 15000 g; 100 µl of the clear supernatants
were transferred into HPLC vials and placed into the autosam-
pler.
For on-line solid-phase extraction a Waters Oasis HLB col-
umn (25 µm, 1.0 × 50 mm; Waters, Milford, USA) was used to-
gether with a Rheodyne six-port high-pressure switching
valve (Rheodyne, Rohnert Park, CA, USA) installed into the
Waters 2690 separation module and controlled by the Micro-
mass Masslynx 3.4 mass spectrometry software (Micromass,
Manchester, UK).
The extraction procedure consisted of three steps: First,
30 µl of deproteinized sample was injected and loaded onto
the extraction column in valve position A (Figure 2); the mo-
bile phase was water/methanol 95/5 v/v delivered at a flow
rate of 3 ml/min; potentially interfering compounds were
washed into the waste. In parallel, the analytical column (Li-
Crospher C18 end-capped 125 × 4 mm; 5 µm, Merck, Darm-
stadt, Germany) was equilibrated with acetonitrile/2 mM am-
monium acetate 80/20 v/v delivered at a flow rate of
0.85 ml/min. After 1 min the switching valve changed to posi-
tion B; the extraction column was now eluted in a back-flush
Figure 1 A: Chemical structure of itraconazole; * denotes the
site of hydroxylation of hydroxyitraconazole. B: Chemical
structure of the itraconazole homolog R51012 used as the in-
ternal standard.
Figure 2 Column switching scheme applied for on-line solid-
phase extraction of itraconazole, hydroxyitraconazole and the
internal standard R51012, respectively.
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mode onto the analytical column. After 2 min the valve
switched back to position A. During analytical chromato-
graphy into the mass spectrometer in position A, the extrac-
tion column was washed with acetonitrile at a flow rate of
3 ml/min for 1 min and subsequently was re-equilibrated with
water/methanol 95/5 v/v. Both extraction and analytical col-
umn were kept at 38 °C in a column oven. The retention times
of itraconazole, hydroxyitraconazole and the internal standard
were approximately 3.6 min, 2.9 min and 3.9 min, respec-
tively, after injection into the extraction column. The total an-
alytical run time was 5 min.
Mass spectrometric conditions
Electrospray atmospheric pressure ionization in the positive
mode was used; the source parameters were tuned to obtain
the following quasi-molecular ions ([M+H+]) of itraconazole,
hydroxyitraconazole and the internal standard compound
(705 m/z, 721 m/z, and 733 m/z, respectively). The following
settings resulted in optimal ion yield: capillary voltage, 3.5 kV;
cone voltage, 55V; source temperature, 90 °C; desolvation
temperature, 250 °C; nitrogen flow, approx. 550 l/h; cone gas
flow, approx. 75 l/h. The collision energy with argon as the col-
lision gas was 35 V. Under these conditions several intense
product ions were generated for all three analytes. For quan-
tification the following transitions were recorded: itraconazole
705>392, hydroxyitraconazole 721>408; internal standard
733>460. The dwell time for all multiple reaction monitoring
(MRM) traces was 0.3 s; interchannel delay and interscan de-
lay were 0.15 s.
Validation
To study the recovery of the two-step extraction procedure
first a solution containing itraconazole, hydroxyitraconazole
and the internal standard each at a concentration of 1000 µg/l
dissolved in methanol/water (1/1) was introduced directly to
the mass spectrometer by loop injection; the peak areas of the
respective multiple reaction monitoring traces were recorded.
Then a drug-free plasma sample was spiked with the three
compounds to obtain the identical final concentration
(1000 µg/l); this sample was submitted to the entire analytical
method described with the only modification that the flow of
the analytical column was reduced to 0.3 ml/min and no split
was applied between HPLC and the mass spectrometer. Again
the respective peak areas of the analytes were recorded and
recoveries were calculated for the three compounds by com-
parison with the respective peak areas obtained by direct
analysis of the pure solution; the experiment was performed
in triplicate.
Linearity of the method was investigated using a spiked
plasma sample with a concentration of 10000 µg/l that was di-
luted stepwise 1+1 with drug-free plasma to a final concen-
tration of 10 µg/l to perform linear regression analysis. The
signal-to-noise ratio of the itraconazole peak and the hydroxy-
itraconazole peak, respectively, of the sample with the lowest
concentration was recorded to estimate the limit of detection
of the method.
To study the imprecision of the method, one plasma pool
each in a high concentration range and in a low concentration
range of itraconazole and hydroxyitraconazole, respectively,
was prepared from residual clinical samples, equilibrated
overnight, aliquoted and stored at –80 °C. In three indepen-
dent series using separately weighted calibration material,
each pool was analyzed 4 times to calculate the respective to-
tal coefficient of variation.
The presence of ion suppression effects was studied by
preparing 1000 µg/l solutions of itraconazole, hydroxyitra-
conazole and the internal standard, respectively, in acetoni-
trile/water (1:1) and separately in drug-free plasma. Both sam-
ples were submitted to the entire method but without addition
of the internal standard. The respective peak areas of the three
analyte-specific multiple reaction monitoring traces were
compared between the two samples (acetonitrile/water vs.
plasma).
Results
The parent ion spectrum of itraconazole obtained by
electrospray ionization is given in Figure 3A; an itra-
conazole molecule containing two Cl-35 atoms (which
represent approx. 75% of naturally occurring chlorine)
has a molecular weight of 704. The mass peak at
705 m/z corresponds to the [M+H]+ ion of this molecule.
The intensive isotope peaks found with m/z ranging up
Figure 3 A: Parent ion spectrum of itraconazole obtained by
electrospray atmospheric pressure ionization in the positive
mode. B: Product ion spectrum of itraconazole generated by
collision induced disintegration of a parent ion with 705 m/z.
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to 710 correspond to itraconazole molecules contain-
ing different proportions of Cl-37 atoms. The mass
peak at 727 m/z represents the sodium adduct of the
itraconazole molecule containing two Cl-35 atoms. The
collision-induced product ion spectrum obtained from
the itraconazole quasi-molecular ion with 705 m/z is
given in Figure 3B.
A representative chromatogram obtained from a
clinical sample is given in Figure 4 (concentration of
itraconazole, 115 µg/l; concentration of hydroxyitra-
conazole 127 µg/l).
Extraction recoveries above 90% were found for itra-
conazole, hydroxyitraconazole and the internal stan-
dard, respectively (itraconazole, mean recovery 92.3%
(SD 1.2%); hydroxyitraconazole, mean recovery 94.0%
(SD 1.4%); internal standard compound, mean recov-
ery 92.7% (SD 1.7%)).
The method proved linear over a range of 10 to
10000 µg/l for both itraconazole and hydroxyitracona-
zole (r > 0.999 for both analytes). In the sample contain-
ing 10 µg/l of itraconazole and hydroxyitraconazole, re-
spectively, a signal-to-noise ratio of 37:1 was found for
the itraconazole MRM peak and of 42:1 for the hydroxy-
itraconazole peak, respectively.
Total imprecision data for the “low concentration”
and the “high concentration” pool are given in Table 1.
Comparison of the peak areas found in a pure solu-
tion of itraconazole, hydroxyitraconazole and the inter-
nal standard, respectively, in methanol/water (1:1) and
found in a plasma sample with the same concentration
of the respective analytes (each 1000 µg/l) did not show
relevant differences, ruling out ion-suppression ef-
fects.
Discussion
In this manuscript, for the first time, a rugged and con-
venient method for the simultaneous quantification of
the anti-mycotic drug itraconazole and its co-active
metabolite hydroxyitraconazole employing LC-TMS is
described.
Validation data demonstrate the applicability of the
method to clinical analyses. The availability of stable
isotope-labeled itraconazole as the internal standard
compound would probably further increase the preci-
sion of the method that at present involves a dimethyl
homolog of itraconazole as the internal standard com-
pound.
Since a preliminary itraconazole target plasma con-
centration for neutropenic patients at risk of systemic
fungal infections has been established (>500 µg/l),
measurement of itraconazole is gaining particular im-
portance for the clinical laboratory. HPLC methods
have been in use for the determination of itraconazole
in plasma for more than 10 years, applying different
techniques of extraction (solvent extraction, solid-
phase extraction or mere protein precipitation), as well
as different techniques of detection (UV, fluorescence,
diode array detection) (18–27, 29, 31). These methods,
however, have important drawbacks with respect to
their specificity. In our experience with conventional
HPLC methods for simultaneous quantification of itra-
conazole and hydroxyitraconazole in a large propor-
tion of individual “drug-free” human plasma samples,
interference arises from undefined compounds that co-
elute with the target analytes. Such interference from
endogenous compounds is found in individual sam-
ples even if analytical run times above 20 min and gra-
dient elution programs are applied.
Specificity of conventional HPLC methods can in
principle be tested with respect to commonly used par-
ent drug compounds; particularly in severely ill patients
treated with large numbers of different drugs and often
Figure 4 Representative chromatograms of itraconazole, hy-
droxyitraconazole and the internal standard R51012 obtained
from a clinical sample (itraconazole, 115 µg/l; hydroxyitra-
conazole, 127 µg/l).
Table 1 Total imprecision data for the quantification of itra-
conazole and hydroxyitraconazole using liquid chromatogra-
phy-tandem mass spectrometry for a low- and a high-analyte




Itraconazole, mean 115 µg/l 994 µg/l
coefficient of variation 5.1% 4.8%
Hydroxyitraconazole, mean 127 µg/l 1150 µg/l
coefficient of variation 5.2% 4.9%
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impaired renal or hepatic function. However, co-elution
of drug metabolites together with itraconazole or hy-
droxyitraconazole (leading to falsely high results) or
with the internal standard compound (leading to falsely
low results) must principally be taken into considera-
tion when unspecific detection techniques such as UV
detection are applied. It is as well a potential limitation
of unspecific techniques of HPLC detection that co-elu-
tion of itraconazole, hydroxyitraconazole or the internal
standard compound, together with one of the many fur-
ther metabolites of itraconazole, may occur. Itracona-
zole is described to be subject to extensive hepatic me-
tabolization; however, very little data is available on this
issue (10, 11). A fully reliable validation of HPLC meth-
ods using conventional techniques of detection would
require all metabolites as pure substances for speci-
ficity investigations. These metabolites, however, are
not generally available. Due to the high specificity of the
LC-TMS technology applied in the method described
here, in contrast to UV or fluorescence detection, ana-
lytical interference from drugs or drug metabolites is
very unlikely. In LC-TMS – after soft ionization of the
compounds having eluted from the HPLC – the parent
ion of a respective target compound is filtered accord-
ing to its mass-to-charge ratio in a first mass spectro-
meter; this parent ion is submitted to disintegration by
collision with argon, generating an analyte-specific
spectrum of product ions. One selected characteristic
ion of these product ions is again filtered according to
its mass-to-charge ratio in a second mass spectrometer
to finally reach the ion detector. Using two mass spec-
trometers in line with an interposed collision cell, po-
tential interference from other drugs, metabolites or
endogenous compounds, as well as unspecific back-
ground “noise”, is minimized in TMS allowing highly
specific and sensitive analyses.
Due to these technical characteristics, LC-TMS in
general requires very limited sample preparation. In
our experience, however, mere protein precipitation as
applied in several previously reported conventional
HPLC methods for itraconazole quantification results in
a short lifetime of the HPLC columns and the electro-
spray capillaries. Moreover, in LC-TMS residual matrix
constituents may interfere with electrospray ionization
of target compounds. Sample preparation by solvent
extraction or manual off-line solid-phase extraction is
time-consuming and would critically limit the sample
throughput. On-line solid-phase extraction after pro-
tein precipitation – as applied in the method described
here – increases the analytical run time by only 1 min
per sample compared to mere protein precipitation
and does not require additional manual handling steps
but this approach results in very stable chromato-
graphic results, efficient ionization and minimal spoil-
ing of the electrospray capillary and ion source parts. In
order to further minimize potential ion suppression ef-
fects after automated sample preparation and to fur-
ther increase specificity (32), a certain degree of chro-
matographic separation has proven to be useful in
TMS assays with overall run times of about 5 min as in
the present method.
Given the typically high plasma concentration ranges
of itraconazole and hydroxyitraconazole, analytical
methods employing single stage liquid chromatogra-
phy-mass spectrometry (LC-MS) systems – which
do not apply the principle of collision-induced genera-
tion of product ions – have been shown to be applicable
to biological samples (28, 30). Compared to single-
stage LC-MS, however, LC-TMS is likely to experience
far more widespread use in clinical laboratories, be-
cause specificity and sensitivity of this latter technology
is by far superior, with the instruments’ costs being
higher by about 30%. Therefore, the convenient
LC-TMS method reported here is of practical interest for
a continuously growing number of laboratories
equipped with LC-TMS systems and offers substantial
improvement in the monitoring of itraconazole and hy-
droxyitraconazole.
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